Literature DB >> 21794025

There were no differences in serum HBV DNA level between HBeAg-positive and HBeAg-negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell volume.

W-M Ke1, S-B Xie, X-J Li, S-Q Zhang, J Lai, Y-N Ye, Z-L Gao, P-J Chen.   

Abstract

Hepatitis B virus (HBV) DNA levels and liver histological necroinflammation grades are correlated with the antiviral efficacy. It is necessary to clarify the relationship between HBV replication levels apportioned by the same hepatic parenchyma cell volume and severity of liver histological necroinflammation grades in both hepatitis B e antigen (HBeAg)-positive and HBeAg-negative chronic hepatitis B. The serum HBV DNA levels apportioned by the same hepatic parenchyma cell volume were compared between HBeAg-positive and HBeAg-negative chronic hepatitis B as well as among liver histological necroinflammation grades 1, 2, 3 and 4, respectively. There were no differences in the serum HBV DNA levels between HBeAg-positive and HBeAg-negative chronic hepatitis B as well as among liver histological necroinflammation grades 1, 2, 3 and 4. However, there were differences in the serum HBV DNA levels apportioned by the same hepatic parenchyma cell volume among liver histological necroinflammation grades 1, 2, 3 and 4 in both HBeAg-positive and HBeAg-negative chronic hepatitis B, respectively. There were no differences in HBV DNA levels with the same liver histological necroinflammation grade activated by HBV wild-type and variant strains. After the differences in hepatic parenchyma cell volume for HBV replication of the same liver histological necroinflammation grade accompanied by different hepatic fibrosis stages were adjusted, the serum HBV DNA level apportioned by the same hepatic parenchyma cell volume was correlated with the severity of liver histological necroinflammation grade.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21794025     DOI: 10.1111/j.1365-2893.2011.01444.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

1.  Evaluation of changes of serum hepatitis B surface antigen from a different perspective.

Authors:  Ze-Qian Wu; Lei Tan; Ting Liu; Zhi-Liang Gao; Wei-Min Ke
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

2.  Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis.

Authors:  Mei-Hong Lin; Hai-Qiong Li; Lin Zhu; Hai-Ying Su; Li-Shan Peng; Chuang-Yuan Wang; Cai-Ping He; Xie-Er Liang; Yan Wang
Journal:  Dig Dis Sci       Date:  2021-05-18       Impact factor: 3.487

3.  Hepatitis C virus load in parenchyma cells correlates with hepatic injury in infected patients.

Authors:  Zhen Xu; Ji-Zong Lin; Guo-Li Lin; Fang-Fang Wei; Jing Liu; Zhi-Xin Zhao; Ying Zhang; Wei-Ming Ke; Xiao-Hong Zhang
Journal:  Exp Ther Med       Date:  2016-11-18       Impact factor: 2.447

4.  The relationship between serum hepatitis B virus DNA level and liver histology in patients with chronic HBV infection.

Authors:  Changjiang Liu; Li Wang; Huizhong Xie; Liyuan Zhang; Bingshu Wang; Chun Luo; Suiqun Wang; Mingliang Tang; Zhongbiao Fu; Hailan Ruan; Zhengjin Liu; Ling Wei; Wenyi Yi; Yunqian Xie
Journal:  PLoS One       Date:  2018-11-07       Impact factor: 3.240

5.  A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase.

Authors:  Ling Li; Yongan Ye; Yun Ran; Shuyan Liu; Qiyuan Tang; Yaya Liu; Xuejiao Liao; Juanjuan Zhang; Guohui Xiao; Jian Lu; Guoliang Zhang; Qing He; Shiping Hu
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

6.  The clinical value of serum hepatic parenchyma cell volume-normalized hepatitis B surface antigen levels in hepatitis B e antigen -positive and -negative chronic hepatitis B patients.

Authors:  Lei Tan; Shi-Lei Xu; Zhi-Shuo Mo; Jian-Rong Liu; Wei-Qiang Gan; Jie-Huan Chen; Zhi-Liang Gao; Ze-Qian Wu
Journal:  Ann Transl Med       Date:  2021-09

7.  Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients.

Authors:  Xingfei Pan; Ka Zhang; Xiaoan Yang; Jiayi Liang; Haixia Sun; Xuejun Li; Yong Zou; Qingqiang Xu; Geng An; Gang Li; Qihuan Xu
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.